Intervention not reported
The mean change of total correct score on the 10/36 SRT from baseline Scale from: 0 to 40 · Patients with memory disorder in multiple sclerosis
1 finding from 1 review
Intervention not reported
The mean change of total correct score on the SDMT from baseline Scale from: 0 to infinity · Patients with memory disorder in multiple sclerosis
1 finding from 1 review
Intervention not reported
The mean change of total correct score on the PASAT (2+3 sec) from baseline Scale from: 0 to 120 · Patients with memory disorder in multiple sclerosis
1 finding from 1 review
Intervention not reported
The number of patients experiencing diarrhoea · Patients with memory disorder in multiple sclerosis
The intervention probably leads to higher the number of patients experiencing diarrhoea (moderate certainty).
1 finding from 1 review
Intervention not reported
The number of patients experiencing nausea · Patients with memory disorder in multiple sclerosis
The intervention showed no clear difference in the number of patients experiencing nausea (moderate certainty).
1 finding from 1 review
Intervention not reported
The number of patients experiencing abnormal dreams · Patients with memory disorder in multiple sclerosis
The intervention probably leads to higher the number of patients experiencing abnormal dreams (moderate certainty).
1 finding from 1 review
Intervention not reported
The annualised rate of relapse Scale from: 0 to infinity. · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Intervention not reported
The sum of the number of gadolinium‐enhancing T1‐weighted lesions Scale from: 0 to infinity. · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Intervention not reported
The number of patients with adverse effects · patients with relapsing‐remitting multiple sclerosis
The intervention showed no clear difference in the number of patients with adverse effects (low certainty).
1 finding from 1 review
Intervention not reported
The number of patients with serious adverse events · patients with relapsing‐remitting multiple sclerosis
The intervention showed no clear difference in the number of patients with serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
The number of patients who withdrew or dropped out from the study because of AEs · patients with relapsing‐remitting multiple sclerosis
The intervention showed no clear difference in the number of patients who withdrew or dropped out from the study… (low certainty).
1 finding from 1 review
Intervention not reported
The number of patients with disability progression · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Intervention not reported
The time to confirmed disease progression · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Intervention not reported
Sustained (6 months) EDSS increase after 3 years · patients with secondary progressive multiple sclerosis
The intervention showed no clear difference in sustained (6 months) EDSS increase after 3 years (high certainty).
1 finding from 1 review
Intervention not reported
Sustained (3 months) EDSS increase after 3 years · patients with secondary progressive multiple sclerosis
The intervention leads to lower sustained (3 months) EDSS increase after 3 years (high certainty).
1 finding from 1 review
Intervention not reported
Sustained (3 or 6 months) EDSS increase at 3 years in patients with pre study relapses · patients with secondary progressive multiple sclerosis
The intervention showed no clear difference in sustained (3 or 6 months) EDSS increase at 3 years in patients with… (high certainty).
1 finding from 1 review
Intervention not reported
Number of patients with at least one relapse during · patients with secondary progressive multiple sclerosis
The intervention leads to lower number of patients with at least one relapse during (high certainty).
1 finding from 1 review
International Index of Erectile Function questionnaire 31 · patients with erectile dysfunction in patients with multiple sclerosis
1 finding from 1 review
International Index of Erectile Function ‐ not reported · patients with erectile dysfunction in patients with multiple sclerosis
1 finding from 1 review
Sexual Encounter Profile questions 2 · patients with erectile dysfunction in patients with multiple sclerosis
Sildenafil showed no clear difference in sexual Encounter Profile questions 2 compared with placebo (low certainty).
1 finding from 1 review